Profusa Lowers Note Conversion Price Floor to $0.20 in Amendment With NorthView Sponsor

Profusa amended its agreement with NorthView Sponsor, lowering the note conversion price floor to $0.20 per share. The conversion price will be the greater of $0.20 or the prior day's closing price. The change applies to conversions on or after the amendment's effective date, November 5, 2026.

Original reporting
Published Nov 6, 2026, 9:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Profusa Lowers Note Conversion Price Floor to $0.20 in Amendment With NorthView Sponsor — source image
Decision brief

The 30-second read

$PFSANeutralLow
01

Why it matters

The amendment lowers the floor price, which could lead to more conversions and share dilution, but the immediate market reaction is likely muted.

02

Market read

Micro‑cap biotech news with limited broader market impact.

03

What to watch

Potential future financing needs could increase conversion likelihood.

Relevance 6/10Novelty 7/10Timing: post-market today

Background

Profusa filed an 8‑K on Nov 6 detailing the amendment to its note conversion terms with NorthView Sponsor.

Company-level read

Ticker impact

$PFSANeutralHigh confidence
Context

Profusa amended its Note Conversion Agreement, lowering the conversion price floor to $0.20 per share.

Expected impact

possible modest downward pressure as investors price in potential dilution.

Evidence & confidence

Amendment changes conversion terms; impact depends on conversion likelihood.

Market effects

May affect other biotech firms with similar convertible note structures.

Limited to US biotech microcap segment.

Minimal.

Counterpoint

If conversion remains unlikely, the amendment may have negligible impact on price.

Key entities

  • Profusa, Inc.

    Biotech company issuing convertible notes.

  • NorthView Sponsor

    Counterparty to the note amendment.

Related articles

$PFSALow

Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company

Profusa, Inc. (PFSA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of w

$MRNAMed

Weekly Buzz: MRNA, NVS, SNY Gain Approvals; EBS, LSTA Cut Jobs; TARS, BIVI Drive Deals & Data

Biotech roundup reports multiple FDA and EU approvals: Replimune’s TUDRIQEV with Bristol Myers Squibb’s nivolumab for advanced melanoma, Takeda’s ORZEYFUL for narcolepsy type 1, Moderna’s mFLUSIVA flu vaccine for adults 50+, Sanofi’s MenQuadfi expanded EU use, and Novartis’ Pluvicto combo for PSMA+ mHSPC. It also covers Lisata layoffs, Emergent restructuring and Q2 results, and deals including Tarsus-Alkeus and Evotec-Odyssey.

$PFSAMedAI 8/10

PFSA Stock Falls 19% Amid Diagnostics Acquisition News

Profusa (PFSA) said it signed a non-binding term sheet to acquire a privately held commercial diagnostics and toxicology testing company. The target estimates 2025 net revenues of about $111 million. Profusa would issue shares equal to 19.99% plus non-voting convertible preferred stock, subject to approval, and expects about $7 million financing via convertible notes. PFSA shares fell sharply after the news.